NASDAQ:EGRX

Eagle Pharmaceuticals Stock Forecast, Price & News

$42.89

-0.55 (-1.27 %)

(As of 06/18/2021 12:00 AM ET)

Add

Compare

Today's Range

$42.20

▼

$43.71

50-Day Range

$36.86

▼

$44.50

52-Week Range

$36.48

▼

$53.43

Volume385,942 shs

Average Volume116,949 shs

Market Capitalization$562.25 million

P/E Ratio40.46

Dividend YieldN/A

Beta0.78

30 days | 90 days | 365 days | Advanced Chart

Receive EGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Zacks: Brokerages Expect Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) to Announce $0.88 EPS
June 19, 2021 | americanbankingnews.com

Eagle Pharmaceuticals Submits Response to Complete Response Letter from FDA for Vasopressin
June 17, 2021 | finance.yahoo.com

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Eagle Pharmaceuticals, Inc.- EGRX
June 11, 2021 | finance.yahoo.com

Return On Capital Employed Overview: Eagle Pharmaceuticals
June 4, 2021 | benzinga.com

Analysts Anticipate Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Will Post Quarterly Sales of $47.30 Million
June 2, 2021 | americanbankingnews.com

Would Shareholders Who Purchased Eagle Pharmaceuticals' (NASDAQ:EGRX) Stock Three Years Be Happy With The Share price Today?
May 30, 2021 | finance.yahoo.com

Eagle Pharmaceuticals (NASDAQ:EGRX) Shares Gap Up to $40.84
May 27, 2021 | americanbankingnews.com

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Eagle Pharmaceuticals, Inc.- EGRX
May 14, 2021 | finance.yahoo.com

Eagle Pharmaceuticals, Inc.'s (EGRX) CEO Scott Tarriff on Q1 2021 Results - Earnings Call Transcript
May 12, 2021 | seekingalpha.com

Eagle Pharmaceuticals Announces Filing of TREAKISYM (bendamustine) Rapid Infusion ("RI") Liquid Formulation in Japan
May 10, 2021 | ca.finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EGRX
Previous Symbol
CUSIPN/A
CIK827871
Webwww.eagleus.com
Phone201-326-5300
Employees106
Year FoundedN/A

Sales & Book Value

Annual Sales$187.80 million
Price / Sales2.99
Cash Flow$1.39 per share
Price / Cash Flow30.87
Book Value$14.27 per share
Price / Book3.01

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares13,109,000
Market Cap$562.25 million
Next Earnings Date8/9/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.41 out of 5 stars

Medical Sector

705th out of 2,097 stocks

Pharmaceutical Preparations Industry

343rd out of 831 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Eagle Pharmaceuticals.

2.9 Community Rank

Outperform Votes
Eagle Pharmaceuticals has received 394 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Eagle Pharmaceuticals has received 297 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Eagle Pharmaceuticals has received 57.02% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Eagle Pharmaceuticals and other stocks. Vote “Outperform” if you believe EGRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Eagle Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Eagle Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eagle Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 22.30% of the stock of Eagle Pharmaceuticals is held by insiders.
Percentage Held by Institutions
92.27% of the stock of Eagle Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5 Earnings and Valuation

Earnings Growth
Earnings for Eagle Pharmaceuticals are expected to grow by 135.90% in the coming year, from $1.17 to $2.76 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eagle Pharmaceuticals is 40.46, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 30.04.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eagle Pharmaceuticals is 40.46, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 44.03.
Price to Book Value per Share Ratio
Eagle Pharmaceuticals has a P/B Ratio of 3.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions

What stocks does MarketBeat like better than Eagle Pharmaceuticals?

Wall Street analysts have given Eagle Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Eagle Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Eagle Pharmaceuticals' next earnings date?

Eagle Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Eagle Pharmaceuticals.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) issued its quarterly earnings results on Monday, May, 10th. The specialty pharmaceutical company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.04. The specialty pharmaceutical company had revenue of $41.25 million for the quarter, compared to analysts' expectations of $45.67 million. Eagle Pharmaceuticals had a trailing twelve-month return on equity of 7.87% and a net margin of 7.89%.
View Eagle Pharmaceuticals' earnings history.

How has Eagle Pharmaceuticals' stock been impacted by COVID-19?

Eagle Pharmaceuticals' stock was trading at $39.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EGRX stock has increased by 9.8% and is now trading at $42.89.
View which stocks have been most impacted by COVID-19.

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the following people:

Mr. Scott L. Tarriff, Founder, Pres, CEO & Director (Age 61, Pay $2.33M)
Mr. David M. Pernock, Chief Operating Officer (Age 68, Pay $1.28M)
Mr. Brian Joseph Cahill, Chief Financial Officer (Age 52)
Mr. Daniel O'Connor, Exec. VP, Chief Strategy Officer & Head of Corp. Devel. (Age 41)
Mr. Michael Moran, Exec. VP and Head of Sales, Bus. Devel. & Gov. Affairs
Dr. Judith Ng-Cashin, Exec. VP & Chief Medical Officer (Age 52)
Mr. John Kimmet, Exec. VP of Marketing Oncology & Acute Care
Dr. Valentin R. Curt M.D., Sr. VP of Clinical Drug Devel.
Dr. Gaozhong Zhu Ph.D., Sr. VP of Pharmaceutical Devel.
Mr. Reiner Nowak, Exec.

Who are some of Eagle Pharmaceuticals' key competitors?

Some companies that are related to Eagle Pharmaceuticals include Centessa Pharmaceuticals (CNTA), Nuvation Bio (NUVB), Revance Therapeutics (RVNC), Deciphera Pharmaceuticals (DCPH), Xencor (XNCR), Organogenesis (ORGO), Ligand Pharmaceuticals (LGND), Zentalis Pharmaceuticals (ZNTL), Seres Therapeutics (MCRB), Amarin (AMRN), Atea Pharmaceuticals (AVIR), Myovant Sciences (MYOV), Ironwood Pharmaceuticals (IRWD), Protagonist Therapeutics (PTGX) and Harmony Biosciences (HRMY).
View all of EGRX's competitors.

What other stocks do shareholders of Eagle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Radius Health (RDUS), bluebird bio (BLUE), Clovis Oncology (CLVS), GW Pharmaceuticals (GWPH) and Incyte (INCY).

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (15.10%), Janus Henderson Group PLC (12.13%), Brandes Investment Partners LP (3.74%), Park West Asset Management LLC (3.43%), Dimensional Fund Advisors LP (2.50%) and Smith Graham & Co. Investment Advisors LP (2.37%).
View institutional ownership trends for Eagle Pharmaceuticals.

Which institutional investors are selling Eagle Pharmaceuticals stock?

EGRX stock was sold by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, Armistice Capital LLC, Citadel Advisors LLC, Janus Henderson Group PLC, Morgan Stanley, Prudential Financial Inc., State Board of Administration of Florida Retirement System, and Renaissance Technologies LLC.
View insider buying and selling activity for Eagle Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Eagle Pharmaceuticals stock?

EGRX stock was bought by a variety of institutional investors in the last quarter, including Brandes Investment Partners LP, Smith Graham & Co. Investment Advisors LP, Kennedy Capital Management Inc., D. E. Shaw & Co. Inc., Acadian Asset Management LLC, Man Group plc, BlackRock Inc., and Federated Hermes Inc..
View insider buying and selling activity for Eagle Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eagle Pharmaceuticals' stock price today?

One share of EGRX stock can currently be purchased for approximately $42.89.

How much money does Eagle Pharmaceuticals make?

Eagle Pharmaceuticals has a market capitalization of $562.25 million and generates $187.80 million in revenue each year. The specialty pharmaceutical company earns $11.99 million in net income (profit) each year or $0.87 on an earnings per share basis.

How many employees does Eagle Pharmaceuticals have?

Eagle Pharmaceuticals employs 106 workers across the globe.

What is Eagle Pharmaceuticals' official website?

The official website for Eagle Pharmaceuticals is www.eagleus.com.

Where are Eagle Pharmaceuticals' headquarters?

Eagle Pharmaceuticals is headquartered at 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]

This page was last updated on 6/20/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here